Brümmendorf, Tim Henrik 1966-
Tim Brümmendorf deutscher Mediziner, Onkologe und Hochschullehrer
Brümmendorf, Tim H.
VIAF ID: 59805727 ( Personal )
Permalink: http://viaf.org/viaf/59805727
Preferred Forms
4xx's: Alternate Name Forms (7)
5xx's: Related Names (3)
- 510 2 _ ‡a Tübingen, Univ
- 510 2 _ ‡a Universitätsklinikum Hamburg-Eppendorf ‡e Affiliation
- 510 2 _ ‡a Universitätsklinikum Hamburg-Eppendorf
Works
Title | Sources |
---|---|
Androgen derivatives improve blood counts and elongate telomere length in adult cryptic dyskeratosis congenita | |
Bosutinib ein neuartiger BCR-ABL-Inhibitor bei vorbehandelten Patienten mit CML | |
Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study | |
Exploiting Synthetic lethality between Germline BRCA1 haploinsufficiency and PARP inhibition in JAK2V617F-positive myeloproliferative neoplasms | |
Immunszintigraphie xenotransplantierter gynäkologischer Tumoren mit monoklonalen Anti-Muzinantikörpern | |
Impaired Overall Survival in Young Patients With Acute Myeloid Leukemia and Variants in Genes Predisposing for Myeloid Malignancies | |
Kit D816V mast cells derived from induced pluripotent stem cells recapitulate systemic mastocytosis transcriptional profile | |
Molekular zielgerichtete Therapie der chronischen myeloischen Leukämie (CML) | |
Practical management of toxicities associated with bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia | |
Protein-protein-interaction network organization of the hypusine modification system | |
Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study | |
Telomerbiologie und zelluläre Alterung in der gesunden und pathologisch gesteigerten Hämatopoese | |
XBP1 promotes NRASG12D pre-B acute lymphoblastic leukaemia through IL-7 receptor signalling and provides a therapeutic vulnerability for oncogenic RAS RAS |